MEI Pharma

MEI Pharma is a clinical-stage pharmaceutical company based in San Diego. Founded to develop and commercialize novel cancer therapies, the company focuses on understanding and leveraging the mechanisms of its drug candidates to optimize efficacy and tolerability. MEI Pharma has several drug candidates in clinical trials, including Zandelisib (formerly called ME-401), Voruciclib, and ME-344. The company's product portfolio consists of various drug candidates targeting hematological malignancies and solid tumors. These candidates are designed to inhibit specific pathways involved in cancer development. MEI Pharma's business model revolves around conducting clinical trials to demonstrate the safety and efficacy of its drug candidates, with the goal of obtaining regulatory approvals and ultimately commercializing these therapies. MEI Pharma is committed to its core values of dedication, shared commitment, personal accountability, mutual trust, and fiscal discipline. The company actively seeks talented individuals to join its team of professionals. Interested parties can connect with MEI Pharma through their website at meipharma.com or explore career opportunities at meipharma.com/careers.